Amgen’s next-generation cholesterol drug ... The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...

Amgen, a global biotechnology leader highlighting profound research and development capabilities and biomanufacturing, showcases its latest achievements in the field of innovative medicines under ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.